CS
CSPHF.US CStone Pharmaceuticals
- Market cap
- USD 1.10B
- P/E
- -
- P/B
- 5.67x
- ROE
- -77.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CSPHF.US undervalued?
Graham numberThe Graham number of CStone Pharmaceuticals cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CStone Pharmaceuticals fundamental analysis
No fundamental analysis for CStone Pharmaceuticals yet.
CStone Pharmaceuticals stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory…
Full company profileCStone Pharmaceuticals financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CStone Pharmaceuticals annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 10.3M | 12.6M | 0.00 | 1.04B | 244M | 481M | 464M | 407M | 263M | 809M |
| Gross Profit | - | 10.3M | 12.6M | - | 797M | 137M | 278M | 304M | 240M | 44.8M | 362M |
| Operating Income | -262M | -242M | -1.03B | -1.74B | -1.09B | -1.83B | -912M | -580M | -91.7M | -421M | -930M |
| EBITDA | -262M | -242M | -1.02B | -1.73B | -1.20B | -1.90B | -850M | -297M | -26.2M | -377M | -841M |
| Net Income | -246M | -309M | -1.75B | -2.31B | -1.22B | -1.92B | -903M | -367M | -91.2M | -426M | -995M |
| EPS | -0.25 | -0.31 | -1.77 | -2.66 | -1.17 | -1.65 | -0.77 | -0.29 | -0.07 | -0.31 | -0.65 |
| Balance Sheet | |||||||||||
| Total Assets | 826M | 564M | 1.63B | 2.95B | 3.76B | 2.27B | 1.64B | 1.66B | 1.39B | 1.36B | 2.06B |
| Total Liabilities | 59.2M | 113M | 1.12B | 469M | 808M | 1.06B | 1.19B | 1.21B | 1.03B | 742M | 763M |
| Shareholders' Equity | 713M | 426M | 515M | 2.48B | 2.95B | 1.21B | 449M | 457M | 364M | 617M | 1.29B |
| Cash & Short-term Investments | 812M | 538M | 1.56B | 2.74B | 3.39B | 1.73B | 1.04B | 1.05B | 673M | 919M | 1.56B |
| Total Debt | - | - | - | 4.34M | 83.9M | 174M | 286M | 363M | 356M | 349M | 357M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -213M | -240M | -791M | -1.08B | -508M | -1.48B | -612M | -589M | -343M | -328M | -885M |
| Capital Expenditure | 1.11M | 12.5M | 7.91M | 10.4M | 71.4M | 149M | 102M | 65.0M | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -214M | -253M | -799M | -1.09B | -580M | -1.63B | -714M | -654M | -343M | -328M | -887M |
| Ratios | |||||||||||
| ROE | -34.5% | -72.5% | -338.7% | -93.0% | -41.3% | -159.1% | -200.9% | -80.4% | -25.1% | -69.0% | -77.0% |
| ROA | -29.8% | -54.7% | -106.9% | -78.2% | -32.4% | -84.5% | -55.1% | -22.1% | -6.5% | -31.3% | -48.4% |
| Net Profit Margin | - | -2,999.1% | -13,906.6% | - | -117.4% | -787.8% | -187.5% | -79.2% | -22.4% | -162.1% | -123.0% |
| Debt to Equity | - | - | - | 0.00x | 0.03x | 0.14x | 0.64x | 0.80x | 0.98x | 0.57x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CStone Pharmaceuticals dividends
CStone Pharmaceuticals has not paid dividends in the last 9 fiscal years.
Who owns CStone Pharmaceuticals
- Insiders 19.94%
- Institutions 16.00%
- Public & others 64.06%
- Shares outstanding 1.59B
- Free float 1.18B
CStone Pharmaceuticals company profile
- Company name
- CStone Pharmaceuticals
- Ticker
- CSPHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 147
- Fiscal year end
- December
- Address
- C1 Building, Suzhou, China, 215123
- Phone
- 86 512 8718 6550
- Website
- cstonepharma.com
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
CStone Pharmaceuticals management
7- Dr. Jianxin Yang M.D., Ph.D.CEO, President of R&D and Executive Director · born 1964
- Ms. Weicong NiCFO & Company Secretary · born 1991
- Ms. Ying Hua ZhangSenior VP & Chief Operating Officer · born 1979
- Mr. Michael J. Choi M.B.A.Chief Business & Strategy Officer · born 1975
- Dr. Yujuan La Ph.D.Senior Vice President of Product Development · born 1978
- Dr. Qingmei Shi M.D., Ph.D.Senior VP & Chief Medical Officer · born 1976
- Dr. Qinzhou Qi Ph.D.VP and Head of R&D Management & Chief of Staff to the CEO · born 1984